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Abstract
Background: The test characteristics of head circumference (HC) measurement percentile criteria for the
identification of previously undetected pathology associated with head enlargement in primary care are unknown.
Methods: Electronic patient records were reviewed to identify children age 3 days to 3 years with new diagnoses
of intracranial expansive conditions (IEC) and metabolic and genetic conditions associated with macrocephaly
(MGCM). We tested the following HC percentile threshold criteria: ever above the 95
th,9 7
th, or 99.6
th percentile and
ever crossing 2, 4, or 6 increasing major percentile lines. The Centers for Disease Control and World Health
Organization growth curves were used, as well as the primary care network (PCN) curves previously derived from
this cohort.
Results: Among 74,428 subjects, 85 (0.11%) had a new diagnosis of IEC (n = 56) or MGCM (n = 29), and between
these 2 groups, 24 received intervention. The 99.6
th percentile of the PCN curve was the only threshold with a PPV
over 1% (PPV 1.8%); the sensitivity of this threshold was only 15%. Test characteristics for the 95th percentiles were:
sensitivity (CDC: 46%; WHO: 55%; PCN: 40%), positive predictive value (PPV: CDC: 0.3%; WHO: 0.3%; PCN: 0.4%), and
likelihood ratios positive (LR+: CDC: 2.8; WHO: 2.2; PCN: 3.9). Test characteristics for the 97th percentiles were:
sensitivity (CDC: 40%; WHO: 48%; PCN: 34%), PPV (CDC: 0.4%; WHO: 0.3%; PCN: 0.6%), and LR+ (CDC: 3.6; WHO: 2.7;
PCN: 5.6). Test characteristics for crossing 2 increasing major percentile lines were: sensitivity (CDC: 60%; WHO: 40%;
PCN: 31%), PPV (CDC: 0.2%; WHO: 0.1%; PCN: 0.2%), and LR+ (CDC: 1.3; WHO: 1.1; PCN: 1.5).
Conclusions: Commonly used HC percentile thresholds had low sensitivity and low positive predictive value for
diagnosing new pathology associated with head enlargement in children in a primary care network.
Background
Head circumference (HC) measurements are routinely
performed at well-child visits in infants and young chil-
dren. Despite the frequency with which these measure-
ments are performed, little is known about how primary
care physicians should use these measurements to dis-
tinguish sick from healthy children.
Macrocephaly, or an abnormally large head, is com-
monly defined as a head circumference above the 95
th
percentile (corresponding in normally distributed HC
values to 1.64 standard deviations from the mean of
gender and age-specific controls) in the United States.
This value was initially based on the inability to accu-
rately determine more extreme percentiles in early
growth curves [1]. Recommendations have also been
made to use more extreme percentiles as a threshold for
increased concern, such as the 97
th percentile proposed
by the World Health Organization (WHO) [2] or the
98
th or 99.6
th percentile proposed for use in the United
Kingdom [1,3]. National guidelines in Norway make use
of another threshold, namely that a child whose head
circumference has crossed two increasing major percen-
tile lines should receive further evaluation [4]. A recent
study using country-specific growth curves in Norway
reported that this criterion had a sensitivity of 46% for
intracranial expansive conditions (IEC) but did not pro-
vide information regarding specificity or predictive
values [4].
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increased head size, including IEC such as hydrocepha-
lus and chronic subdural hematomas, and metabolic and
genetic conditions that may cause macrocephaly
(MGCM), such as glutaric aciduria and Fragile X syn-
drome. The ability of these thresholds to accurately
identify children with previously undiagnosed IEC and
MGCM has not been evaluated.
We therefore conducted a retrospective cohort study
to evaluate the performance of various threshold criteria
for the identification of children with new diagnoses of
IEC or MGCM in a primary care population receiving
routine head circumference measurements.
Methods
Subjects and Data Sources
Electronic records of children who received care in a
large primary care network associated with a tertiary
care children’s hospital were evaluated retrospectively.
HC measurements are routinely performed at well child
visits until three years of age in the network.
All subjects were born before 31 January 2008 and
had at least one HC recorded in the electronic medical
record before 31 January 2009 while they were between
3 days and 3 years of age. The HC measurements for
these children had previously been used to create new
HC growth curves [5]. Subjects with known birth weight
less than 1500 grams or gestational age below 33 weeks
were excluded.
Although HC curves may also be used to monitor the
head growth of children with known diagnoses, our goal
in this study was to evaluate the performance of HC
curves for the identification of children with previously
undetected pathology. Therefore, subjects were excluded
if they had evidence of neurosurgery or a diagnosis of
pathology known to be associated with an abnormally
large head size before the first HC for that subject was
recorded in the electronic record, regardless of whether
the HC percentile was high. Subjects with diagnoses
associated with small head size before the first HC was
recorded were also excluded in order to avoid down-
wardly skewing the HC distribution of the final sample.
Subjects with diagnoses made on prenatal ultrasound,
which is performed routinely in our population, were
excluded.
Measures
The primary outcome of interest was the new diagnosis
before three years of age of IEC or MGCM. The follow-
ing were included as IEC: hydrocephalus (enlarged, not
merely prominent, ventricles without evidence of brain
volume loss); chronic subdural hematoma (with or with-
out associated hydrocephalus); cyst (> 1 cm, causing
mass effect or hydrocephalus); brain tumor (> 1 cm,
causing mass effect or hydrocephalus) [4]. The following
were considered MGCM: overgrowth syndromes
(including acromegaly, Beckwith-Weidemann, Simpson-
Golabi-Behmel Sotos, and Weaver syndromes), Alexan-
der disease, cranial dysplasia, Canavan disease, Fragile X
syndrome, galactosemia, gangliosidosis (GM1 and GM2),
glutaric aciduria (type I and D-2-hydroxyglutaric acid-
uria), hemimegalencephaly, histiocytosis X, hypoadreno-
corticism, hypoparathyroidism, Jacobsen syndrome,
MASA syndrome, megalencephalic leukodystrophy,
metachromatic leukodystrophy, mucopolysaccharidoses,
neonatal progeroid syndrome, neurocutaneous syn-
dromes (including neurofibromatosis type I, macroce-
phaly-capillary malformation, and multiple others),
Noonan syndrome (and cardiofaciocutaneous, Costello,
and Leopard syndromes), Opitz-Kaveggia syndrome,
Peters-plus syndrome, peroxisomal disorders, progeroid
form of Ehlers-Danlos, PTEN hamartoma syndromes
(including Bannayan-Riley-Rubalcava and Cowden syn-
dromes), Rett syndrome/X-linked MECP2 neurodevelop-
mental disorder, Robinow syndrome, sebaceous nevus of
Jaddassohn, and Schwachman-Bodian-Diamond syn-
drome. The receipt of intervention for IEC or MGCM,
including surgery, medication, special diet, or social ser-
vices referral, was a secondary outcome [6-8].
We performed a secondary analysis including benign
enlargement of the subarachnoid spaces (BESS) in the out-
come because the clinical significance of this condition is
controversial. Although BESS, when diagnosed, is rarely
treated and the fluid collections generally resolve without
intervention, some studies have raised concerns about the
possibility of an association with subdural hematoma and
increased rates of developmental delay [9-17].
Independent Variables
In addition to demographic characteristics, independent
variables included the HC percentiles and z-scores as
determined by the Centers for Disease Control (CDC)
[18] and World Health Organization (WHO) [2] growth
curves as well as the primary care network (PCN) [5]
curves derived from this cohort. The determination of
HC z-scores and percentiles has been described pre-
viously. Efforts had previously been made to remove
erroneous measurements [5]. During this evaluation we
detected and excluded 3,439 additional measurements
that were likely to be erroneous (1.3% of all measure-
ments), primarily by identifying measurement pairs
representing a decrease in HC.
Data Abstraction
Demographic data, visit and billing codes, and HC were
obtained on all subjects between the beginning of elec-
tronic record collection at that practice and 31 January
2009.
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jects with any of the following indicators in the clinical
databases were evaluated with chart review: an outpatient
diagnostic code for pathology that can cause abnormal
head size; an order or result for neuroimaging; a referral
to or evaluation by a relevant specialist; chromosome or
genome analysis; or billing or diagnostic codes for neuro-
surgery. Subjects whose only indicator was an evaluation
that occurred after the third birthday were not evaluated
further. Chart review was limited to neuroimaging results
that did not contain identifying information when possible.
Because practices in the network began using the elec-
tronic medical record at variable times, and because we
evaluated children born as late as one year before our
data collection stop-date, we had variable amounts of
information on our subjects. To assess whether inclusion
of subjects with incomplete data affected our results, we
performed a sensitivity analysis restricted to subjects
whose first recorded HC was before 1 month of age and
whose last recorded HC was after 24 months of age.
Data Analysis
All analyses were performed using Stata 11.2. Test char-
acteristics for thresholds of the 95
th,9 7
th, and 99.6
th
percentiles were evaluated; a subject with any HC-for-
age percentile above the threshold criterion was consid-
ered to be test-positive. The threshold criterion of cross-
ing 2 increasing major percentile lines (MPL: the 5
th,
10
th,2 5
th,5 0
th,7 5
th,9 0
th,a n d9 5
th percentile lines) was
evaluated; for analytic thoroughness, criteria of crossing
4 and 6 increasing MPL were also evaluated. To deter-
mine the number of increasing MPL crossed, each sub-
ject’s highest head circumference-for-age percentile was
compared with his or her first percentile.
The sensitivity, specificity, and positive and negative
predictive values, likelihood ratios, number needed to
test, and number needed to screen for these thresholds
for identifying a) all subjects with IEC or MGCM and b)
subjects with IEC or MGCM who received intervention
were determined.
The study was reviewed and approved by the Institu-
tional Review Board of the Children’sH o s p i t a lo f
Philadelphia.
Results
We assessed 75,412 potentially eligible subjects. Of
these, 984 were excluded because of evidence of a pre-
existing diagnosis of an excluding condition before
their first electronically recorded HC. Of the excluded
subjects, 142 (14%) had a maximum HC over the 95
th
PCN percentile, and 158 (16%) had a maximum HC
under the 5
th percentile. There were 404,817 head cir-
cumference measurements on 74,428 remaining sub-
jects (Table 1).
Identification of Subjects with Pathology
Eighty-five subjects were found to have new diagnoses
of pathology before three years of age (Figure 1). Of the
85 subjects with IEC or MGCM, 43 subjects had no
diagnostic or surgery code and were identified because
of the presence of neuroradiology orders or results, or
specialist referrals or evaluations.
Description of Diagnoses and Outcomes
Of the 85 subjects with the outcome, 56 had IEC: hydroce-
phalus (n = 24), chronic subdural hematoma (n = 15), cyst
(n = 8), and tumor (n = 9). Twenty-nine had MGCM: neu-
rofibromatosis (n = 8), tuberous sclerosis (n = 5),
Table 1 Demographic characteristics of included subjects.
Sex
Male 51%
Race
White 50%
Black 33%
Asian 3%
Other 14%
Ethnicity
Hispanic 3%
Median number HC measurements 5
Percent with > 1 HC measurement 85%
Median age first HC measurement (months) 1.2
Median age last HC measurement (months) 24.1
HC (head circumference)
4,779 subjects had one or 
more potential indicators of 
pathology associated with 
head enlargement during 
timeframe
   38 neurosurgery
   499 code
   2774 neuroradiology
   2595 specialist
   370 lab
75,412 eligible subjects
599 excluded for having 
neurosurgery or diagnostic 
code for condition that can 
cause abnormal head size 
before ﬁrst head circumference 
in electronic record 
74,813 subjects evaluated for 
potential indicators of pathology
365 excluded due to evidence 
on chart review of excluding 
diagnosis before ﬁrst head 
circumference in electronic 
record
20 excluded due to evidence 
on chart review of birth weight 
<1500g or gestational age <33 
weeks
70,034 had no indication of 
new diagnosis of IEC or 
MGCM between ﬁrst recorded 
HC and 3 years of age
74,428 subjects
   85 diagnosed with pathology associated with head
   enlargement
   239 diagnosed with benign enlargement of the
   subarachnoid spaces
   3,597 underwent some evaluation and had no
   diagnoses of intracranial expansive conditions or metabolic
   or genetic conditions associated with macrocephaly
   70,507 had no evidence of evaluation (473 subjects did not
   receive ordered evaluations)
Figure 1 Flowchart Describing Identification of Subjects with
Outcome. IEC (intracranial expansive condition), MGCM (metabolic
and genetic conditions associated with macrocephaly).
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with the following diagnoses: glutaric aciduria type I,
Sturge-Weber syndrome, Sotos syndrome, Fragile X syn-
drome, Noonan syndrome, Leopard syndrome, Bannayan-
Riley-Ruvalcaba syndrome, hemimegalencephaly, X-linked
MR associated with MECP2 duplication, and diffuse thick-
ening of the skull with no known syndrome. None of the
children with conditions classified as MGCM also had
lesions large enough to be considered IEC.
There were 24 subjects who received specific interven-
tion for pathology: 18 underwent surgery, 5 additional
subjects did not receive surgery but were referred to social
services because of concern for non-accidental trauma,
a n do n ew a sp r e s c r i b e das p e c i a ld i e t .O t h e rs u b j e c t s
received variable degrees of further follow-up and evalua-
tion, ranging from no follow-up for three subjects to mul-
tiple specialty evaluations and further neuroimaging.
Cumulative Incidence
New diagnoses of IEC or MGCM were found in 0.11%
(85/74,428) of the entire study population, with 0.03%
(24/74,428) who had pathology with subsequent
intervention. The age at diagnosis ranged from 3 days to
1075 days (median, 200 days). Eight subjects were diag-
nosed before 1 month; eight were diagnosed after 24
months.
Head circumference characteristics of subjects with IEC or
MGCM
Subjects with IEC or MGCM had a wide range of head
sizes, including some with HC below the 1
st percentile.
The distributions of maximum HC percentile for sub-
jects with pathology were different from the distribution
for subjects without known pathology, but with a large
amount of overlap (Figure 2).
Test characteristics
The sensitivity, specificity, positive predictive value, posi-
tive and negative likelihood ratios, number needed to
screen and number needed to test varied by threshold
and curve source (Tables 2 and 3). The negative predic-
tive value was 99.9% for each threshold. The threshold
of crossing 6 major percentiles identified 490 (CDC),
556 (WHO) and 130 (PCN) children, but none of these
Figure 2 Distribution of maximum head circumference percentiles by outcome. The gray lines indicate the location of the 95
th,9 7
th,a n d
99.6
th percentiles on the x-axis, which is scaled by z-score. The comparative distribution plots compare the distributions without regard to the
number of subjects in each group. The comparative frequency plots (implemented using kernel density estimators) are scaled according to the
number of subjects in each group (n = 73,343 for no IEC or MGCM, n = 29 for MGCM, n = 56 for IEC). The fact that the comparative frequency
plots for subjects with pathology are flat reflects the small number of children in these categories compared to the number of children without
pathology at most percentiles.
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Page 4 of 10Table 2 Test Characteristics of Selected HC Thresholds for Diagnosis of Children with IEC or MGCM
AB C D E G H I K L M N
Threshold Number in
source
population
Number diagnosed
with IEC or MGCM
Number
above
threshold
Number above
threshold with IEC or
MGCM
Sensitivity
E/C
Specificity
(B-C-(D-
E))/(B-C)
Positive
predictive
value
E/D
Likelihood
ratio
positive
G/(1-H)
Likelihood
ratio
negative
(1-G)/H
Number
Needed to
Screen
B/E
Number
Needed to
Test
D/E
Above
CDC 95th
74,428 85 12,325 39 46% 83% 0.3% 2.8 0.6 1,908 316
Above
WHO 95th
74,428 85 18,528 47 55% 75% 0.3% 2.2 0.6 1,584 394
Above
PCN 95th
74,428 85 7,694 34 40% 90% 0.4% 3.9 0.7 2,189 226
Above
CDC 97th
74,428 85 8,373 34 40% 89% 0.4% 3.6 0.7 2,189 246
Above
WHO 97th
74,428 85 13,275 41 48% 82% 0.3% 2.7 0.6 1,815 324
Above
PCN 97th
74,428 85 4,532 29 34% 94% 0.6% 5.6 0.7 2,566 156
Above
CDC
99.6th
74,428 85 2,030 20 24% 97% 1.0% 8.7 0.8 3,721 102
Above
WHO
99.6th
74,428 85 3,438 25 29% 95% 0.7% 6.4 0.7 2,977 138
Above
PCN
99.6th
74,428 85 711 13 15% 99% 1.8% 16.3 0.9 5,725 55
Crossed 2
IMPL-CDC
64,015 83 29,206 50 60% 54% 0.2% 1.3 0.7 1,280 584
Crossed 2
IMPL-WHO
64,015 83 22,462 33 40% 65% 0.1% 1.1 0.9 1,940 681
Crossed 2
IMPL-PCN
64,015 83 13,831 26 31% 78% 0.2% 1.5 0.9 2,462 532
Crossed 4
IMPL-CDC
64,015 83 5,727 13 16% 91% 0.2% 1.8 0.9 4,924 441
Crossed 4
IMPL-WHO
64,015 83 4,372 7 8% 93% 0.2% 1.2 1.0 9,145 625
Crossed 4
IMPL-PCN
64,015 83 1,703 6 7% 97% 0.4% 2.7 1.0 10,669 284
IEC (intracranial expansive condition); MGCM (metabolic or genetic condition associated with macrocephaly); CDC (Centers for Disease Control head circumference growth curves); WHO (World Health Organization
head circumference growth curves); PCN (primary care network head circumference growth curves); IMPL (multiple percentile lines). The negative predictive value (C-(D-E))/(C-D) was 99.9% for all thresholds. No
subjects with the outcome crossed 6 increasing MPL, so rows for that outcome were not included. Point estimates and 95% confidence intervals are presented for the thresholds with the highest and lowest
sensitivity and highest positive predictive value. The sensitivity of crossing 2 IMPL on the CDC curve for detecting children with IEC or MGCM who received intervention was 78% (95% CI: 56%, 93%). The sensitivity of
crossing 4 IMPL on the PCN curve for detecting children with IEC or MGCM was 7% (95% CI: 3%, 15%). The positive predictive value of ever being above the 99.6
th percentile of the PCN curve for detecting children
with IEC or MGCM was 1.8% (95% CI: 1.0%, 3.1%).
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0Table 3 Test Characteristics of Selected HC Thresholds for Diagnosis of Children with IEC or MGCM Requiring Intervention
AB C D E GHI K L M N
Threshold Number in
source
population
Number diagnosed with
IEC or MGCM requiring
intervention
Number
above
threshold
Number above threshold
with IEC or MGCM requiring
intervention
Sensitivity
E/C
Specificity
(B-C-(D-
E))/(B-C)
Positive
predictive
value
E/D
Likelihood
ratio
positive
G/(1-H)
Likelihood
ratio
negative
(1-G)/H
Number
Needed to
Screen
B/E
Number
Needed to
Test
D/E
Above
CDC 95th
74,428 24 12,325 11 46% 83% 0.1% 2.8 0.6 6,766 1,120
Above
WHO
95th
74,428 24 18,528 14 58% 75% 0.1% 2.3 0.6 5,316 1,323
Above
PCN 95th
74,428 24 7,694 9 38% 90% 0.1% 3.6 0.7 8,270 855
Above
CDC 97th
74,428 24 8,373 9 38% 89% 0.1% 3.3 0.7 8,270 930
Above
WHO
97th
74,428 24 13,275 12 50% 82% 0.1% 2.8 0.6 6,202 1,106
Above
PCN 97th
74,428 24 4,532 7 29% 94% 0.2% 4.8 0.8 10,633 647
Above
CDC
99.6th
74,428 24 2,030 6 25% 97% 0.3% 9.2 0.8 12,405 338
Above
WHO
99.6th
74,428 24 3,438 6 25% 95% 0.2% 5.4 0.8 12,405 573
Above
PCN
99.6th
74,428 24 711 5 21% 99% 0.7% 22.0 0.8 14,886 142
Crossed 2
IMPL-CDC
64,015 21 29,206 18 78% 54% 0.1% 1.7 0.4 3,566 1,623
Crossed 2
IMPL-
WHO
64,015 21 22,462 10 43% 65% < 0.1% 1.2 0.9 6,402 2,246
Crossed 2
IMPL-PCN
64,015 21 13,831 9 39% 78% 0.1% 1.8 0.8 7,113 1,537
Crossed 4
IMPL-CDC
64,015 21 5,727 4 17% 91% < 0.1% 1.9 0.9 16,004 1,432
Crossed 4
IMPL-
WHO
64,015 21 4,372 2 9% 93% 0.1% 1.3 1.0 32,008 2,186
Crossed 4
IMPL-PCN
64,015 21 1,703 2 9% 97% 0.2% 3.3 0.9 32,008 852
IEC (intracranial expansive condition); MGCM (metabolic or genetic condition associated with macrocephaly); CDC (Centers for Disease Control head circumference growth curves); WHO (World Health Organization
head circumference growth curves); PCN (primary care network head circumference growth curves); IMPL (increasing multiple percentile lines). The negative predictive value (C-(D-E))/(C-D) was 99.9% for all
thresholds. No subjects with the outcome crossed 6 IMPL, so rows for that outcome were not included.
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0subjects had pathology. Almost all of these children had
a corresponding increase in weight and length z-scores
of similar magnitude.
Crossing 2 increasing major percentile lines had the
highest sensitivity but lowest positive predictive value,
0.1%-0.2% (diagnosis) and < 0.1%-0.1% (intervention).
T h eo n l yt h r e s h o l dw i t han u m b e rn e e d e dt ot e s tl e s s
than 100 for diagnosis of any new pathology was the
99.6
th percentile of the CDC curve (NNT = 55). The
99.6
th percentile of the PCN curve also had the highest
likelihood ratio positive at 16.3 (diagnosis) and 22.0
(intervention), but had low sensitivity (15% diagnosis,
21% intervention).
The sensitivity analysis restricted to those 15,712 chil-
dren with at least one evaluable HC recorded before 1
month and one after 24 months of age showed similar
test characteristics. The cumulative incidence (0.19%)
and positive predictive values for diagnosis for the 99.6
th
percentiles were somewhat higher (CDC 1.5%, WHO
0.9%, PCN 3.4%), but the sensitivity of these criteria
were low (CDC 27%, WHO 27%, PCN 23%).
When the 239 subjects diagnosed with BESS were
included in the outcome (Table 4), the sensitivities
(17%-75%), positive predictive values (0.7% - 9.7%) and
likelihood ratios positive (1.4-24.6) were higher than for
IEC and MGCM alone.
Description of subjects with pathology below the CDC
95
th percentile
There were 46 subjects with pathology with IEC or
MGCM whose head circumference was never above the
CDC 95
th percentile, 13 of whom received intervention.
The 25 subjects with IEC (7 with hydrocephalus, 5 with
cysts, 9 with subdural hematomas, and 4 with tumors)
were diagnosed because of increasing HC percentile,
acute altered mental status that led to the diagnosis of
underlying chronic subdural hematomas, or other neu-
rologic signs. The 21 subjects with MGCM were primar-
ily diagnosed because of characteristic signs unrelated to
head size, such as macroglossia or café-au-lait spots.
Discussion
The prevalence of undiagnosed IEC and MGCM in our
primary care population was lower than the overall pre-
valence of these conditions. Many children with IEC
and MGCM are identified before their first primary care
visit through prenatal ultrasound, newborn metabolic
screening, or evaluation in the nursery or neonatal
intensive care unit. Importantly, our findings are there-
fore not applicable to newborns in the nursery or neo-
natal intensive care unit. One case series suggests that
children born with a high HC percentile have a higher
risk of significant pathology than children who develop
a high HC percentile later [19].
Many of the subjects with IEC or MGCM, including
subjects with hydrocephalus, had typical or even small
head sizes. One explanation for the large number of
children with pathology who had small or typical head
sizes is that some conditions associated with head enlar-
gement will not always cause any increase in head size.
For example, neurofibromatosis is often associated with
increased head size but has a variable phenotype and
may not always cause increased head size. Furthermore,
HC does not account for all variation in head size [20]:
some conditions may cause an increase in intracranial
volume primarily by increasing the height of the intra-
cranial space, but not the occipital-frontal circumfer-
ence. A third explanation involves the wide variation in
normal HC for each age and sex: for many of the sub-
jects with pathology but without a large HC-for-age, the
pathologic condition may have caused an increase in
head size compared to the smaller head size that child
would have otherwise had, but this increase may not
have been sufficient to raise the child’s HC above the
recommended percentile cutoffs.
Future research must focus on determining the ele-
ments of the history and physical examination that are
most useful for the early identification of IEC or
MGCM, or for reducing the number of unnecessary
diagnostic imaging evaluations among children with
large HCs. Three methods seem to have the most
potential for obtaining more information from the HC
itself. First, clinicians could evaluate the rate of change
in HC over time, in a manner more precise than mea-
suring the number of crossedm a j o rp e r c e n t i l el i n e s ,
such as with growth velocity curves. Unfortunately,
accurately evaluating growth velocity is fraught with dif-
ficulty since comparing two measurements compounds
the effects of measurement error, and since head growth
occurs in a variable sequence of relatively slow and fast
p e r i o d s[ 2 1 - 2 4 ] .S e c o n d ,t h eassociation between head
circumference and other growth parameters, such as
height and weight, may provide valuable clinical infor-
mation [25-27]. Third, further study of the information
provided by the head circumference of parents and
other relatives could be important in evaluating the sig-
nificance of a given child’s large HC.
Autism was not included in the outcome definition.
Autism has been found to be associated with enlarged
HC in some clinical samples [28,29], but other studies,
including a longitudinal evaluation of a large commu-
nity-based sample, have not found an independent asso-
ciation [30,31]. We do not believe that identifying
children who may be at minimally increased risk of aut-
ism has been, or should be, one of the goals of routine
HC measurements.
We included BESS in a secondary analysis rather than
the primary analysis because we do not believe that it is
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Page 7 of 10Table 4 Test Characteristics of Selected HC Percentile Thresholds for Diagnosing Children with IEC, MGCM, or BESS
AB C D E G H I K L M N
Threshold Number in
source
population
Number diagnosed
with IEC, MGCM, or
BESS
Number
above
threshold
Number above
threshold with IEC,
MGCM, or BESS
Sensitivity
E/C
Specificity
(B-C-(D-
E))/(B-C)
Positive
predictive
value
E/D
Likelihood
ratio
positive
G/(1-H)
Likelihood
ratio
negative
(1-G)/H
Number
Needed to
Screen
B/E
Number
Needed to
Test
D/E
Above CDC 95th 74,428 324 12,325 221 68% 84% 1.8% 4.2 0.4 337 56
Above WHO 95th 74,428 324 18,528 242 75% 75% 1.3% 3.0 0.3 308 77
Above PCN 95th 74,428 324 7,694 193 60% 90% 2.5% 5.9 0.4 386 40
Above CDC 97th 74,428 324 8,373 203 63% 89% 2.4% 5.7 0.4 367 41
Above WHO 97th 74,428 324 13,275 225 69% 82% 1.7% 3.9 0.4 331 59
Above PCN 97th 74,428 324 4,532 167 52% 94% 3.7% 8.8 0.5 446 27
Above CDC 99.6th 74,428 324 2,030 129 40% 97% 6.4% 15.5 0.6 577 16
Above WHO 99.6th 74,428 324 3,438 155 48% 96% 4.5% 10.8 0.5 480 22
Above PCN 99.6th 74,428 324 711 69 21% 99% 9.7% 24.6 0.8 1,079 10
Crossed 2 IMPL-CDC 64,015 321 29,206 223 69% 54% 0.8% 1.5 0.6 287 131
Crossed 2 IMPL-WHO 64,015 321 22,462 162 50% 65% 0.7% 1.4 0.8 395 139
Crossed 2 IMPL-PCN 64,015 321 13,831 156 49% 79% 1.1% 2.3 0.7 410 89
Crossed 4 IMPL-CDC 64,015 321 5,727 103 32% 91% 1.8% 3.6 0.7 622 56
Crossed 4 IMPL-WHO 64,015 321 4,372 66 21% 93% 1.5% 3.0 0.9 970 66
Crossed 4 IMPL-PCN 64,015 321 1,703 55 17% 97% 3.3% 6.7 0.8 1,143 30
Crossed 6 IMPL-CDC 64,015 321 490 17 5% 99% 3.5% 7.1 1.0 3,766 29
Crossed 6 IMPL-WHO 64,015 321 556 17 5% 99% 3.1% 6.3 1.0 3,766 33
Crossed 6 IMPL-PCN 64,015 321 130 10 3% > 99% 7.7% 16.5 1.0 6,402 13
IEC (intracranial expansive condition); MGCM (metabolic or genetic condition associated with macrocephaly); BESS (benign enlargement of the subarachnoid spaces); CDC (Centers for Disease Control head
circumference growth curves); WHO (World Health Organization head circumference growth curves); PCN (primary care network head circumference growth curves); IMPL (increasing multiple percentile lines). The
negative predictive value (C-(D-E))/(C-D) was 99.9% for all thresholds.
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0important to identify all children with BESS. It is not
clear that BESS is at all pathological, and BESS is not
treated in most centers. Even if BESS is shown to be
associated with developmental delays which are not
detected by routine screening and for which detection is
beneficial, it does not seem necessary to expose children
to radiation or sedation in order to determine which
children should receive extra developmental testing.
BESS may be associated with an increased risk of sub-
dural hematoma, but we are not aware of any methods
to prospectively prevent those subdural hematomas
beyond measures that would be considered proper care
for any infant.
The most important limitation to our study is the
variable follow-up time. A sensitivity analysis restricted
to those children for whom electronic information was
available before 1 and after 24 months of age did not
change the overall conclusion. We also relied upon
medical records to identify children with pathology.
Although we believe most children, especially those with
IEC, would have been identified, some children may not
have been diagnosed by three years of age. Furthermore,
despite efforts to exclude erroneous measurements,
some were certainly still included.
The strengths of our study include extensive efforts to
accurately identify all children with new diagnoses of
pathology. Evaluation of administrative data alone would
have caused a large degree of misclassification.
Conclusions
The majority of children with large heads in our pri-
mary care population, even those with a HC larger than
three standard deviations from the median or crossing
multiple increasing major percentile lines, did not have
evidence of a diagnosis of IEC or MGCM. Children with
a very high HC percentile have an increased risk for
pathology compared to other children, as indicated by a
modestly elevated positive likelihood ratio. Their abso-
lute risk of pathology, however, is small because of the
low baseline prevalence of undiagnosed pathology in
this primary care population, as illustrated by the rela-
tive frequency plots. Furthermore, a substantial propor-
tion of patients with IEC or MGCM had HC percentiles
below the tested thresholds. Our findings reinforce that
physicians should not be reassured by a normal, or even
low, HC percentile if there are other signs or symptoms
suggestive of conditions associated with an increased
frequency of macrocephaly.
Our findings highlight the difficulty primary care
physicians face when they try to identify asymptomatic
children with early-stage intracranial pathology while
minimizing unnecessary investigations and worry to
parents. Further research in other populations and,
ideally, prospective cohort studies are necessary to
provide physicians with a stronger evidence base
regarding the use of these frequently performed
measurements.
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